Choosing liraglutide Liraglutide is also an injectable GLP-1 receptor agonist, however, it is administered daily
doi: 10.1016/j.tifs.2020.02.001 15
Additionally, manufacturing pills at a massive scale might eventually help ease the supply shortages that have plagued popular injectable GLP-1s, though this is not yet guaranteed
The SURMOUNT-3 trial had 806 obese adults without T2D undergo 12 weeks of intensive lifestyle intervention, before randomizing the 579 participants who lost 5% of their body weight to receive either tirzepatide or a placebo
This is better for long-term health optimization as well as longevity, Cho says
In educating themselves and seeking support, patients can lay a robust foundation for achieving their weight loss goals with Tirzepatide